SCHEMBL11633136

SCHEMBL11633136

O=C(O)c1n[nH]c(=S)[nH]c1=O

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
GAA P10253 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPT P10636 1/20 0.43
MEN1 O00255 1/20 0.43
KDM3B Q7LBC6 1/20 0.42
RXFP1 Q9HBX9 4/20 0.41
PPARG P37231 3/20 0.41
NCOA2 Q15596 3/20 0.41
NCOA1 Q15788 3/20 0.41
NCOA3 Q9Y6Q9 3/20 0.41
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
HCAR2 Q8TDS4 8/20 0.39
LDHA P00338 1/20 0.39
LDHB P07195 1/20 0.39
NPSR1 Q6W5P4 1/20 0.37
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL829306 0.82 CYP2D6 (0.43) ALDH1A1GAAKMT2AMAPTMEN1
SCHEMBL6046336 0.81 ALDH1A1 (0.44) ALDH1A1GAAKMT2AMAPTMEN1
SCHEMBL17281433 0.81 MAPT (0.46) ALDH1A1GAAKMT2AMAPTMEN1
Hydrochloric Acid SCHEMBL11324175 0.80 CYP2D6 (0.42) ALDH1A1GAAKMT2AMAPTMEN1
SCHEMBL5269625 0.72 POLB (0.54) ALDH1A1GAAKMT2AMAPTRXFP1
SCHEMBL1196085 0.70
SCHEMBL5791378 0.67 ALDH1A1 (1.00) ALDH1A1GAAKMT2AMAPTMEN1
SCHEMBL17272789 0.65 MAPT (0.61) ALDH1A1GAAKMT2AMAPTMEN1
SCHEMBL15859525 0.65 HCAR2 (0.55) ALDH1A1KMT2AHCAR2LDHALDHB
SCHEMBL28136550 0.64 NSD2 (0.47) ALDH1A1GAAKMT2AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119220636-A Biological activity detection kit based on luciferase reporter gene 大连博格林生物科技有限公司 2024-12-31 CN claimed
CN-119220636-A Biological activity detection kit based on luciferase reporter gene 大连博格林生物科技有限公司 2024-12-31 CN disclosed
US-20230293524-A1 OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY SPIRAL THERAPEUTICS INC. 2023-09-21 US disclosed
EP-3661932-B1 COMPOSITIONS AND METHODS FOR STABILIZING BENZOTHIAZOLE LUCIFERIN ANALOGS PROMEGA CORP (US) 2021-10-06 EP disclosed
US-11136615-B2 Compositions and methods for stabilizing benzothiazole luciferin analogs PROMEGA CORPORATION (US) 2021-10-05 US disclosed
US-11136615-B2 Compositions and methods for stabilizing benzothiazole luciferin analogs PROMEGA CORPORATION (US) 2021-10-05 US disclosed
WO-2021087408-A1 OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY OTONOMY, INC. (US) 2021-05-06 WO disclosed
EP-3661932-A1 COMPOSITIONS AND METHODS FOR STABILIZING BENZOTHIAZOLE LUCIFERIN ANALOGS Promega Corporation (US) 2020-06-10 EP disclosed
US-20190040449-A1 COMPOSITIONS AND METHODS FOR STABILIZING BENZOTHIAZOLE LUCIFERIN ANALOGS JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2019-02-07 US disclosed
WO-2019028272-A1 COMPOSITIONS AND METHODS FOR STABILIZING BENZOTHIAZOLE LUCIFERIN ANALOGS PROMEGA CORPORATION (US) 2019-02-07 WO disclosed
US-20190040449-A1 COMPOSITIONS AND METHODS FOR STABILIZING BENZOTHIAZOLE LUCIFERIN ANALOGS JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2019-02-07 US disclosed
EP-3146066-B1 COMPOSITIONS AND METHODS FOR STABILIZING LUMINOGENIC SUBSTRATES PROMEGA CORP (US) 2018-03-14 EP disclosed
US-9676997-B2 Compositions and methods for stabilizing luminogenic substrates PROMEGA CORPORATION (US) 2017-06-13 US disclosed
US-9676997-B2 Compositions and methods for stabilizing luminogenic substrates PROMEGA CORPORATION (US) 2017-06-13 US disclosed
EP-3146066-A1 COMPOSITIONS AND METHODS FOR STABILIZING LUMINOGENIC SUBSTRATES Promega Corporation (US) 2017-03-29 EP disclosed
US-20150337198-A1 COMPOSITIONS AND METHODS FOR STABILIZING LUMINOGENIC SUBSTRATES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2015-11-26 US disclosed
WO-2015179864-A1 COMPOSITIONS AND METHODS FOR STABILIZING LUMINOGENIC SUBSTRATES PROMEGA CORPORATION (US) 2015-11-26 WO disclosed
US-20150337198-A1 COMPOSITIONS AND METHODS FOR STABILIZING LUMINOGENIC SUBSTRATES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2015-11-26 US disclosed
US-4081441-A PENICILLANIC ACIDS BRISTOL-MYERS COMPANY (US) 1978-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190040449-A1 COMPOSITIONS AND METHODS FOR STABILIZING BENZOTHIAZOLE LUCIFERIN ANALOGS TK1, TYMP, NUDT1 ALDH1A1 2006/4885GAA 1393/4885KMT2A 1287/4885
US-11136615-B2 Compositions and methods for stabilizing benzothiazole luciferin analogs TK1, TYMP, NUDT1 ALDH1A1 2006/4885GAA 1393/4885KMT2A 1287/4885
US-20230293524-A1 OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY OTC, SLC26A4, OAT ALDH1A1 121/4885GAA 2616/4885KMT2A 4008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.